期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在急性冠脉综合征中的应用进展 被引量：3

Application of Platelet Glycoprotein Ⅱb/Ⅲa Receptor Inhibitors in Acute Coronary Syndrome
下载PDF
导出
摘要 血栓形成在急性冠状动脉血管闭塞中起关键作用。而血小板的活化和聚集在血栓形成过程中起着核心作用。血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂作用的靶点即是各种致血小板聚集和血栓形成的最终共同途径。现就血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在急性冠状动脉综合征中的应用进展作一综述。 Thrombosis plays an important role in acute coronary obstruction.The activation and coagulation of platelets are a key part.The target which platelet glycoprotein Ⅱb/Ⅲa inhibitors act on is the final common step in platelet aggregation.This article shows progress made in the application of platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndrome.
作者 陈平 马依彤
机构地区 新疆医科大学第一附属医院心脏中心冠心病科
出处 《心血管病学进展》 CAS 2010年第6期843-846,共4页 Advances in Cardiovascular Diseases
基金 自治区科技攻关和重点项目计划(课题编号200733146-3)
关键词 急性冠状动脉综合征 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂 acute coronary syndrome platelet glycoprotein Ⅱb/Ⅲa inhibitors
分类号 R541.41 [医药卫生—心血管疾病]
  • 相关文献

参考文献25

  • 1Karvouni E,Katritsis DG,Ioannidis JP,et al.Intravenous glycoprotein Ⅱb/Ⅲa receptor antagonists reduce mortality after percutaneous coronary interventions[J].J Am Coll Cardiol,2003,41(1):26-32.
  • 2Kandzari DE,Hasselblad V,Tcheng JE,et al.Improved clinical outcomes with abciximab therapy in acute myocardial infarction:a systematic overview of randomized clinical trials[J].Am Heart J,2004,147(3):457-462.
  • 3Kandzari DE,Berger PB,Kastrati A,et al.Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization[J].J Am Coll Cardiol,2004,44:2133-2136.
  • 4Iijima R,Ndrepepa G,Mehilli J,et al.Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment[J].Clin Res Cardiol,2008,97(3):160-168.
  • 5Cura FA,Bhatt DL,Lincoff AM,et al.Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein Ⅱb/Ⅲa inhibition in complex atherosclerotic lesions[J].Circulation,2000,102:28-34.
  • 6Kini A,Reich D,Marmur JD,et al.Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions:results of the Rota ReoPro randomized trial[J].Am Heart J,2001,142:965-969.
  • 7Stone GW,Bertrand ME,Moses JW,et al.Routine upstream initiation vs deferred selective use of glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes:The ACUITY timing trial[J].JAMA,2007,297(6):591-602.
  • 8Montalescot G,Borentain M,Payot L,et al.Early vs late administration of glycoprotein Ⅱb/Ⅲa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction:a meta-analysis[J].JAMA,2004,292(3):362-366.
  • 9Stone GW,Grines CL,Cox DA,et al.A prospective,multicenter,international randomized trial comparing four perfusion strategies in acute myocardial infarction:Principal report of the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial[J].J Am Coll Cardiol,2001,37(suppl 2):S342.
  • 10Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GP Ⅱb/Ⅲa inhibitors during primary percutaneous coronary interventionin acute myocardial infarction patients[J].J Incasive Cardiol,2005,17:296-299.

同被引文献26

引证文献3

二级引证文献6

心血管病学进展
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部